Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
POLICY PAPERS
November 28, 2022
The experience of the COVID-19 pandemic—in the US and around the world—highlights the potential feasibility and importance of biomedical R&D for global health and welfare. Drawing from this experience and momentum, this paper argues that the US should deepen its engagement and ambition in global hea...
Blog Post
November 28, 2022
Building on the success of Operation Warp Speed, the US should deepen its engagement and ambition in global health R&D to drive transformative improvements in global health outcomes and security. Specifically, it should consider a subscription model for new antimicrobials; an advance market commitme...
POLICY PAPERS
November 15, 2022
Antimicrobial drugs form the backbone of modern medicine. Yet over time, use of these drugs selects for mutations that survive exposure to those same drugs, driving “antimicrobial resistance,” or AMR. In the absence of sufficient R&D investment for new antimicrobials, deaths from drug-resistant infe...
Blog Post
October 04, 2022
Most R&D money flows from the private sector, which aims to maximize returns on investment. As a result, health R&D largely skews towards rich countries’ priorities and health system technical capacities, leaving significant gaps in diseases that primarily affect poor and marginalized populations.
POLICY PAPERS
October 04, 2022
In this paper, we report the results of a horizon-scanning exercise to source opportunities for global health R&D investment—that is, high-value potential biomedical innovations which are currently underfunded but which could be transformative for health, quality of life, and health security in LMIC...
Blog Post
April 13, 2022
Tuberculosis, once highly prevalent across Europe and North America, has largely been forgotten in the West but remains a heavy burden in low- and middle-income countries. Now, as rich countries vaccinate (and boost) their populations against COVID-19, lift restrictions, and slowly return to “normal...
Blog Post
January 20, 2022
Last October we asked our readers to weigh in on promising opportunities for pull mechanisms to help drive high-value global health innovation. This blog highlights our interim findings, with great gratitude to the 25+ individuals and groups who took the time for a conversation.
POLICY PAPERS
August 11, 2021
To help the US government make broader use of pull approaches, this policy paper surveys the ways in which US government authorities, budgetary rules, and procurement approaches either facilitate or constrain use of pull mechanisms to support R&D. It specifically focused on the budgetary “scorin...
CGD NOTES
August 11, 2021
Over the past two decades, partnerships between bilateral and multilateral funders, philanthropy, national governments, and the private sector have substantially increased global access to effective malaria treatment. Nevertheless, further action on malaria case management is needed to meet global t...